May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Comparative Ocular Histopathological Effects of Eye Drops Containing Purite(R) (Oxychloro Complex) or Benzalkonium Chloride Preservatives in Rabbits
Author Affiliations & Notes
  • A. Oyejide
    Safety Evaluation-Pathology, Allergan Inc, Irvine, CA, United States
  • S. Matsumoto
    Safety Evaluation-Toxicology, Allergan Inc, Irvine, CA, United States
  • J. Chang
    Formulations Dev., Allergan Inc, Irvine, CA, United States
  • K. Tarlo
    Formulations Dev., Allergan Inc, Irvine, CA, United States
  • M. Holland
    Formulations Dev., Allergan Inc, Irvine, CA, United States
  • S.M. Whitcup
    Clinical Ophthalmology, Allergan Inc, Irvine, CA, United States
  • B. Short
    Clinical Ophthalmology, Allergan Inc, Irvine, CA, United States
  • Footnotes
    Commercial Relationships  A. Oyejide, Allergan Inc. E; S. Matsumoto, Allergan Inc. E; J. Chang, Allergan Inc E; K. Tarlo, Allergan Inc. E; M. Holland, Allergan Inc. E; S.M. Whitcup, Allergan Inc. E; B. Short, Allergan Inc. E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1365. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      A. Oyejide, S. Matsumoto, J. Chang, K. Tarlo, M. Holland, S.M. Whitcup, B. Short; Comparative Ocular Histopathological Effects of Eye Drops Containing Purite(R) (Oxychloro Complex) or Benzalkonium Chloride Preservatives in Rabbits . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1365.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: New, non-irritating preservatives are especially needed for ophthalmic products when the treatment is chronic or when the ocular surface is compromised as in dry eye. The microscopic ocular effects of repeat dosing with eye drops containing a conventional preservative, benzalkonium chloride (BAK), or a new preservative, Purite(R) (stabilized oxychloro complex), were compared. Methods: New Zealand white rabbits (3/group) received in the left eye, 2 drops (6 times/day for 7 days) of 150, 250, or 500 ppm Purite(R) in 0.5% carboxymethylcellulose (CMC), 150 ppm Purite(R) in phosphate buffer, or 100 ppm BAK in phosphate buffer. The right eye served as the untreated control. The parameters evaluated were ocular discomfort, gross ocular observations, slit lamp biomicroscopy, and ocular histopathology. Results: Treatment with 100 ppm BAK in phosphate buffer caused transient minimal ocular discomfort (43% frequency). The frequency of minimal ocular discomfort in the Purite(R) groups was 0 - 5% (p<0.001 in comparison with BAK group). Treatment with BAK caused transient mild ocular hyperemia (14% frequency), whereas no hyperemia noted in the Purite(R) treatment groups. Treatment with BAK caused minimal to mild degeneration of the corneal epithelium and minimal to mild goblet cell loss in the conjunctiva (100% incidence). By contrast, for all Purite(R) treatment groups combined, the only histopathological lesion was minimal goblet cell loss (8% incidence, p<0.001). Conclusions: Eye drops containing Purite(R) were better tolerated than those containing BAK as measured by ocular response and histology in the rabbit. Purite(R) provides a non-irritating preservative that may be especially useful for ophthalmic products used chronically or with a compromised ocular surface.

Keywords: cornea: epithelium • conjunctiva • pathology: experimental 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×